EGFR and non-small cell lung carcinoma: The ADAURA clinical study, probing the efficacy of adjuvant osimertinib therapy, has unveiled notable amelioration in disease-free survival for early and locally advanced non-small cell lung carcinoma patients bearing EGFR mutations [22].